Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Apr 26, 2024; 16(4): 168-172
Published online Apr 26, 2024. doi: 10.4330/wjc.v16.i4.168
Pacemaker post transcatheter aortic valve replacement: A multifactorial risk?
Stephane Noble, Karim Bendjelid
Stephane Noble, Department of Medicine, Structural Heart Unit, University Hospital of Geneva, Geneva 1211, Switzerland
Karim Bendjelid, Department of Acute Medicine, Geneva University Hospitals, Geneva 1211, Switzerland
Co-corresponding authors: Stephane Noble and Karim Bendjelid.
Author contributions: Noble S wrote the first draft; and both authors interpreted the data, critically revised the manuscript for important intellectual content, gave approval for the final version to be published and affirmed that the manuscript is an honest, accurate, and transparent account of the study being reported.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Stephane Noble, MD, Assistant Professor, Department of Medicine, Structural Heart Unit, University Hospital of Geneva, 4 rue Gabrielle Perret Gentil, Geneva 1211, Switzerland. stephane.noble@hcuge.ch
Received: November 21, 2023
Peer-review started: November 21, 2023
First decision: January 24, 2024
Revised: February 1, 2024
Accepted: March 18, 2024
Article in press: March 18, 2024
Published online: April 26, 2024
Core Tip

Core Tip: Since the first transcatheter aortic valve replacement (TAVR) in 2002, TAVR has become a recognized alternative therapy to symptomatic severe aortic stenosis independently of the surgical risk score. The multiple iterations of the delivery systems and transcatheter heart valves (THV) over time associated with better patient assessment and the growing experience and expertise of the operators improved the procedural and follow-up results. However, despite the possibility of repositioning and partially recapturing some of the self-expanding THV and generally higher implantation targets, the need for a permanent pacemaker remains the most frequent complication post-procedure.